Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.74 |
| ▸ | MTOR | P42345 | 3/20 | 0.74 |
| ▸ | SMG1 | Q96Q15 | 3/20 | 0.74 |
| ▸ | CDK2 | P24941 | 3/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.74 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.74 |
| ▸ | CDK4 | P11802 | 2/20 | 0.74 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.74 |
| ▸ | CCND1 | P24385 | 2/20 | 0.74 |
| ▸ | CDK7 | P50613 | 2/20 | 0.74 |
| ▸ | CCNH | P51946 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | XBP1 | P17861 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.74 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905384 | 0.96 | CDK1 (0.71) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL4897031 | 0.94 | MTOR (0.64) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL4897306 | 0.88 | CSNK2A1 (0.73) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL7813208 | 0.87 | MTOR (0.57) | CDK1MTORSMG1CDK2CDK5 | |
| Ethylenediamine SCHEMBL7811225 | 0.87 | CSNK2A1 (0.71) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL6107154 | 0.87 | MTOR (0.55) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL7813711 | 0.86 | CSNK2A1 (0.57) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL6110038 | 0.86 | AURKA (0.60) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL6109957 | 0.85 | MTOR (0.54) | CDK1MTORSMG1CDK2CDK5 | |
| SCHEMBL1574530 | 0.85 | CDK1 (1.00) | CDK1MTORSMG1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | claimed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | claimed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| US-7109197-B2 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1292190-B1 | N-PHENYL-4-(4-PYRIDYL)-2-PYRIMIDINEAMINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. | 2003-12-25 | — | — | US | disclosed |
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | HRH4, HRH3, HRH2 | CDK1 2196/4885MTOR 4509/4885SMG1 1422/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | CDK1 264/4885MTOR 1338/4885SMG1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.